Autism Spectrum Disorders (ASD) Pervasive brain developmental disorders causing severe impairment in thinking, feeling, communication, eye contact and ability to relate to others, repetitive behavior Seen first in early childhood Includes Autism, Aspergers, etc. Genetic and environmental toxic linkage (heavy metals, infections, chemicals) Treatments include diet, behavior modification, psychoactive drugs, antioxidants, chelators
Northern California Autism Study 18 Autism patients (66% mycoplasma-positive) (various species, incl. M. fermentans, M. pneumoniae, M. hominis) 42 Family members (36 adults, 17 CFS-symptomatic, 19 healthy) (CFS ~53% positive, incl. M. fermentans, M. pneumoniae, M. hominis) Healthy Family Members (2/19, 10.5% myco-pos) Difference between Autism or CFS and Healthy Family members, P<0.001 Med. Veritus 2005; 2:383-387. Prof. G. L. Nicolson The Institute for Molecular Medicine
Journal of Neuroscience Research 2007; 85:1143-1148.
Includes Journal of Neuroscience Research 2007; 85:1143-1148. P<0.0001 P<0.001 P<0.001
CA vs. TX
Co-Infections in ASD Patients Mycoplasma species (40-65%) Borrelia species (10-30%) Chlamydia species (5-10%) Other Bacteria (??) HHV-6 (15-30%) CMV (5-10%) Other Viruses (??) Fungal Infections (5-20%?)
QuickTime and a TIFF (LZW) decompressor are needed to see this picture.
Percent of Lyme Disease Patients with Mycoplasmal Infections M. fermentans M. pneumoniae M. genitalium 0% 20% 40% 60% 80% M. hominis M. penetrans M. fermentans +M. pneumoniae M. fermentans +M. hominis M. fermentans +M. geniltalium Lyme Disease Patients All Single + Multiple Infections All Multiple Infections 20% of Total Infections Prof. G. L. Nicolson Institute for Molecular Medicine
Ly m e D is ea se D iag n os is & Th er ap y Su gg estions 2 0 06 A CA M M eet in g DI A GNO S IS AND THER A P Y OF C H RON IC SY S TE M IC C O -I N F ECTIO N S IN LY M E DI S EA S E AND OT H ER TIC K- BORNE IN F EC T IOU S DI S EA S ES P ro f. Ga rt h L. N i co ls on T he I ns titu te for M olecu lar Med ici ne ( We bs ite w w w. im m e d.o rg ) 1 63 71 G otha rd Str ee t H, H un ti n gton Be ach, CA 9 26 47 T he d iag n o s is of L ym e D isea se s h o u ld b e b ase d o n c lin ic al an d la b ora tor y d ata as w el l as t h e like lih o o d o f e x p o s u re to the L y m e s p ir o che te. Mo s t L y m e D isease p at ien ts ha v e m u ltip le c o -i n fect io n s. In ad d itio n to th e L ym e s p iroc h ete (B or relia b u rg d o r fe ri ), th e m ajor ity of L ym e pa tie n ts are a ls o inf ecte d w ith tic k - b o rn e my co p la sm a, ricke tts ia an d /or pr o t o zo a. T h ere are a n u mb er o f co n s idera tio n s w h en u n der g o in g th era p y for mu l ti p le in fect io n s fo u n d in chr o n ic illn ess es, in clu d in g w he ther to u se tra d itio na l as we ll as in tegra tiv e n u traceu tica l ap p roac h es. T h ese are d isc u s sed in th e fo llo w in g s ect io n s, in cl u d in g an tib io tic /an ti p ro toz o an t h erap ies a n d d ietary s u p p le m en ts. _ L ym e D is eas e is the mo st co mm on ti ck-bo rne d isea s e in No rt h A m e ri ca and h a s been repo rt ed in 48 U. S. st a tes and i n Ea st e r n C a nada. F ound in O ld Ly m e, C T i n 1975, t he i nfe c tion i s cau sed by a tick b i te and the e n t ry i nto t he sk in a pprox im a t e ly 24 hou rs l a te r o f the sp ir a l- shaped sp ri oche te B orr el ia burgdo rf er i [1 ] and o t he r co -i n fec tions. B orr el ia and it s co -i nf e c tion s c an b e ca rri ed in t o new h a bi ta ts by a var ie t y o f ticks, s uch as t he d e er tick, bl ack -l egged tic k and bea r tick, and t he ir vec to r s, such a s r oden ts, bi rd s and o the r an im a ls. A ft e r it s incuba tion fo r a f ew day s to a m on th, t he B orr el ia sp ri oche t e a nd a ls o it s co -i nf e c tion s mi g ra t e through the sk i n and in t o t he ly m ph and bl ood wh e re it c a n d iss e mi na t e to nea r and d is ta n t site s i n t he ho st [2 ]. T ran sp l acen ta l t ra ns mi ssi on o f B orr el ia (and it s co- in f ec tion s) can occu r i n pregn a nt an im a ls, inc l ud ing hu m an s, and blood - bo r ne tran sm issi on by b lood tran sf us ion is li ke ly but unp r oven. T he tick -bo r ne co -i n fec tions can and u s ua ll y do appea r at the sa m e tim e and m ay al so be in t rodu c ed by tick b it e s. T hes e w ill b e d i sc us sed i n t hi s bri e f r ev iew of Ly me D is eas e d i agno s is and t re at m e nt.
Mitochondrial Function is Impaired in Most Chronic Clinical Conditions Due to Damage to Mitochondrial Membranes. This damage can be repaired by Replacement of Membrane lipids
Mitochondrial Dysfunction Plays an Important Role in: Mycoplasma Infections Are Commonly Found in These Diseases Neurodegenerative Diseases Neurobehavioral Disorders Fatiguing Illnesses Autoimmune Diseases Respiratory Diseases Rheumatic Diseases Gastrointestinal Disorders Genitourinary Diseases Immunosuppressive Diseases
Lyme Disease, Mycoplasma & Mitochondrial Function Some patients diagnosed with CFS or ASD are later found to have Lyme Disease Intracellular Infections in CFS, ASD and Lyme Disease increases ROS (Reactive Oxygen Species) ROS oxidize/damage membrane lipids and DNA Mitochondrial membranes and mtdna are especially sensitive to ROS damage Oxidized mitochondrial membranes cause reductions in oxidative phosphorylation/energy Oxidized cellular membranes cause reductions in membrane function
ROS Damage to cellular Membranes
What The Institute is Lipid for Molecular Replacement Medicine Therapy? It is the natural replacement of oxidized or damaged lipids using lipid supplements that are protected from oxidation/damage Nicolson, G.L. J Amer Nutraceut Assoc 2003; 6(3):22-28. Nicolson, G.L. Pathol Oncol Res 2005; 11:139-144. Nicolson, G.L. J. Chronic Fatigue Synd 2006; 13(4):57-68 Nicolson, G.L. J Amer Nutraceut Assoc 2010; 13(1):11-15. Download at www.immed.org
What The Institute is Lipid for Molecular Replacement Medicine Therapy? Membrane Repair Mixture Contains: -Membrane PLs: PC, PS, PI, PG, etc. -Probiotics -Growth Factors for Probiotics -Antioxidants (Vit E) Some Mixtures Contain: Vitamin B-Complex
Clinical Trials Summary Condition or Illness Aging, Fatigue Chronic Fatigue CFS CFS/FMS Aging, Fatigue Average Age Piper Fatigue 70.1 35.5% reduction 50.3 40.5% reduction 44.8 58.3 43.1% reduction 36.8% in one week Significance P<0.001 P<0.0001 P<0.0001 P<0.0001
Mean Fluorescence Mitochrondrial Function in Subjects Treated with PL Mixture Determined by Uptake of 2uM Rh123 2000 1500 1000 1050 P<0.001 1388 P<0.00001 P<0.00001 1626 1659 500 0 Base Line 30 Days 60 Days 90 Days Treatment with NT Factor